Blinded Evaluation News Today

Equities analysts forecast that Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) will post earnings of ($0.93) per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Cytokinetics’ earnings. The highest EPS estimate is ($0.75) and the lowest is ($1.02). Cytokinetics reported earnings of ($0.66) per share during the same […]

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) have earned a consensus recommendation of “Buy” from the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. […]

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) have been assigned a consensus recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company. […]

State of Alaska Department of Revenue reduced its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 2.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,390 shares of the biopharmaceutical company’s stock after selling 1,530 shares during the quarter. State […]

American International Group Inc. grew its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) by 12.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 50,099 shares of the biopharmaceutical company’s stock after purchasing an additional 5,550 shares during the quarter. American International Group Inc.’s holdings in Cytokinetics were worth $1,791,000 as […]

Balyasny Asset Management LLC acquired a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) during the third quarter, HoldingsChannel reports. The firm acquired 36,915 shares of the biopharmaceutical company’s stock, valued at approximately $1,319,000. Several other hedge funds and other institutional investors have also modified their holdings of the company. Bain Capital Public Equity […]

Jefferies Group LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 72,500 shares of the biopharmaceutical company’s stock, valued at approximately $2,591,000. Other large investors also recently made changes to their […]

Investegate announcements from Infant Bacterial Therapeutics, A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes